Scinai Immunotherapeutics (NASDAQ: SCNI) has announced the appointment of Eran Kuratz as head of supply chain and business process administration for its wholly owned subsidiary, Scinai Biopharma Services Ltd. This strategic move comes as the company expands its contract development and manufacturing organization (CDMO) platform, aiming to enhance operational efficiency and support its growth trajectory.
Kuratz brings over 30 years of leadership and operational experience across the pharmaceutical, biotechnology, medical-device, and industrial sectors. In his new role, he will oversee critical functions including procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity, and cross-functional business processes. His expertise is expected to streamline operations and reinforce the company's commitment to delivering high-quality services to its clients.
The appointment follows Scinai's expansion of its CDMO platform through the first-quarter 2026 acquisition of Recipharm Israel, which added a second development and manufacturing site in Yavne. Combined with Scinai's Jerusalem operations, the expanded platform now offers a comprehensive range of capabilities, including biologics process development, aseptic manufacturing, sterile fill-and-finish, small-molecule active pharmaceutical ingredient development and synthesis, analytical-method development, and GMP manufacturing. This enhanced infrastructure positions Scinai to meet the growing demand for CDMO services in the biopharmaceutical industry.
The strategic significance of this appointment lies in Scinai's focus on optimizing its expanded operations. By bringing in a seasoned leader like Kuratz, the company aims to integrate its newly acquired capabilities seamlessly, ensuring that its supply chain and business processes are robust enough to support the increased scale. This is critical for maintaining operational excellence and customer satisfaction as the company grows.
Scinai Immunotherapeutics is a biopharmaceutical company dedicated to developing innovative immunology therapies. The company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. In addition, Scinai owns Scinai Biopharma Services Ltd., a CDMO that provides development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.
The CDMO business has become a key growth driver for Scinai, offering services that range from early-stage development to commercial manufacturing. With the addition of the Yavne site, the company now has a stronger foothold in the market, capable of serving a broader client base. The appointment of Kuratz is a clear signal that Scinai is committed to building a world-class operational framework to support this expansion.
According to industry analysts, the global CDMO market is expected to grow significantly in the coming years, driven by increasing outsourcing of manufacturing by pharmaceutical and biotech companies. Scinai's strategic investments and leadership appointments position it well to capitalize on this trend. The company's ability to deliver high-quality services efficiently will be a key differentiator in this competitive landscape.
For more information on this announcement, the full press release is available at https://ibn.fm/d9ktl. For the latest news and updates about Scinai Immunotherapeutics, visit their newsroom at https://ibn.fm/SCNI.
